ReviewActa diabetologica2026
Mitochondrial structural and functional aberrations in diabetic bladder dysfunction: underlying mechanisms and therapeutic landscapes.
Review in Acta diabetologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Diabetic bladder dysfunction (DBD) is a prevalent complication of diabetes mellitus (DM), characterized by heterogeneous urological impairments including altered bladder sensation, decreased compliance, and voiding difficulties. Emerging evidence highlights mitochondrial structural and functional aberrations as pivotal drivers of DBD pathogenesis. Chronic hyperglycemia induces excessive mitochondrial reactive oxygen species (ROS) generation, cristae disruption, impaired fission-fusion dynamics, defective mitochondrial quality control, and calcium dysregulation, collectively impairing bladder smooth muscle cell (BSMCs) bioenergetics and promoting apoptosis, inflammation, and fibrotic remodeling. These processes culminate in progressive bladder dysfunction, transitioning from compensatory hyperactivity to decompensated underactivity. Mitochondria-targeted therapeutic architectures fall into two complementary categories: repurposed guideline-based pharmacological agents and conceptual prospective interventions, the latter encompassing molecular reprogramming, cell-based therapies, and cell-free regenerative platforms. This review synthesizes current mechanistic insights into mitochondrial involvement in DBD and explores potential therapeutic landscapes, emphasizing the need for integrated, mechanism-driven interventions to advance clinical management of this condition.
Indexed as
Identifiers
42658249What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.